FTC Warns ‘Junk Patents’ Could Make Drugs Like Ozempic Pricier—Here’s How
The FTC sent warning letters to 10 pharmaceutical companies—including Novo Nordisk, AstraZeneca, GlaxoSmithKline and Teva—disputing more than 300 “junk” patent listings across 20 different brand name products, the agency said Tuesday.